

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



PERSONAL INFORMATIONS

Name CARLO TUMSCITZ
CF
Telephone n.
Fax
E-mail
Nationality
Date of birth

WORK EXPERIENCES

2004 Cardiology, Ospedale Degli Infermi Rimini, Italy.
2004 Cardiology Ospedale Guglielmo Da Saliceto di Piacenza, Italy
Senior Interventional Cardiologist
2009 Employed by Azienda Ospedaliero-Universitaria di Ferrara
• Name and address Azienda Ospedaliero-Universitaria di Ferrara
Via Aldo Moro, 8 – 44124 Cona, Ferrara
Daily activity in Cardiology and interventional Cardiology wards. On duty activity emergent PCI for ACS

EDUCATION

2000 Degree in Medicine at University of Bologna with highest grade (**110/110 e lode**);
2004 Specialization in Cardiology at Florence University with highest grade (**70/70 e lode**)

FIRST LANGUAGE

ITALIAN

OTHER LANGUAGES

• reading
• writing
• oral expression

ENGLISH

Very good
Very good
Very good

FRENCH, SPANISH

• reading
• writing
• oral expression

Sufficient
Not sufficient
Sufficient

PROFESSIONAL SKILLS

Principal e co-investigator of several national and international clinical studies
Speaker in several National and International Cardiologic Conferences
Adjunct Professor of Cardiology of the Cardiology School of University of Ferrara (Italy) since 2013

TECHNICAL SKILLS

Expert in complex PCI structural and coronary image: **IVUS, NIRS, FFR, Angiojet thrombectomy in coronary and pulmonic system, Filterwire, Laser (ELCA), Rotablator, Aortic Valvuloplasty via femoral and radial approach (pioneer of this novel approach), TAVI.**

ADDITIONAL SKILLS

ACLS Instructor since 2014 with American Heart Association
Fellow of the Italian invasive cardiology association (SICI-GISE) since 2016
Associate member (since 2015) and later **Full Member of EURO CTO Club** since 2017
Musician and composer of the Italian Society of authors and composers (SIAE) since 1999
Member of “**HEART and MUSIC for LIFE**” Association since 2010, created by physicians with the aim of charitable fund raising.

DRIVING LICENCE

AB

Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.

Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurkowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopcuk J, Hamm C, Steg PG, Heg D, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators.

J Am Coll Cardiol. 2019 Nov 5;74(18):2223-2234. doi: 10.1016/j.jacc.2019.08.1038.

Radial Artery Access for Percutaneous Cardiovascular Interventions: Contemporary Insights and Novel Approaches.

Scalise RFM, Salito AM, Polimeni A, Garcia-Ruiz V, Virga V, Frigione P, Andò G, Tumscitz C, Costa F. J Clin Med. 2019 Oct 18;8(10). pii: E1727. doi: 10.3390/jcm8101727. Review.

Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.

Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, de Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll HP, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, Valgimigli M.

Eur Heart J. 2019 Aug 14;40(31):2595-2604. doi: 10.1093/euroheartj/ehz453.

Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial.

Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Asano T, Katagiri Y, van Geuns RM, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek JJ, Spitzer E, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Serruys PW.

EuroIntervention. 2019 Aug 9;15(6):e539-e546. doi: 10.4244/EIJ-D-19-00184.

Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY).

Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurkowski A, van Geuns RJ, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopcuk J, Hamm C, Steg G, Heg D, Jüni P, Windecker S, Valgimigli M.

BMJ Open. 2019 Mar 9;9(3):e026053. doi: 10.1136/bmjopen-2018-026053.

Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study.

Tebaldi M, Biscaglia S, Tumscitz C, Del Franco A, Gallo F, Spitaleri G, Fileti L, Serenelli M, Tonet E, Erriquez A, Campo G, Ferrari R.

Cardiology. 2018;140(2):74-82. doi: 10.1159/000488852. Epub 2018 Jun 13.

Antegrade and retrograde approach through the venous graft for treating a chronic total occlusion in a patient with acute coronary syndrome complicated by pulmonary edema].

Gallo F, Tebaldi M, Tumscitz C.

G Ital Cardiol (Rome). 2018 Jan;19(1):67-70. doi: 10.1714/2852.28781.

Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial.

Gargiulo G, Ariotti S, Vranckx P, Leonardi S, Frigoli E, Ciociano N, Tumscitz C, Tomassini F, Calabò P, Garducci S, Crimi G, Andò G, Ferrario M, Limbruno U, Cortese B, Sganzerla P, Lupi A, Russo F, Garbo R, Ausiello A, Zavalloni D, Sardella G, Esposito G, Santarelli A, Tresoldi S, Nazzaro MS, Zingarelli A, Petronio AS, Windecker S, da Costa BR, Valgimigli M.

JACC Cardiovasc Interv. 2018 Jan 8;11(1):36-50. doi: 10.1016/j.jcin.2017.09.014.

Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?

Gargiulo G, Heg D, Ferrari F, Percoco G, Campo G, Tumscitz C, Colombo F, Zuffi A, Castriota F, Cremonesi A, Windecker S, Valgimigli M.

J Am Heart Assoc. 2017 Dec 23;6(12). pii: e007150. doi: 10.1161/JAHA.117.007150.

A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial.

Biscaglia S, Tonet E, Pavasini R, Serenelli M, Bugani G, Cimaglia P, Gallo F, Spitaleri G, Del Franco A, Aquila G, Vieceli Dalla Segna F, Tebaldi M, Tumscitz C, Ferrari R, Campo G.

PLoS One. 2017 Aug 23;12(8):e0182124. doi: 10.1371/journal.pone.0182124. eCollection 2017.

Per ulteriori informazioni:

www.cedefop.eu.int/transparency

www.europa.eu.int/comm/education/index_it.html

www.eurescv-search.com

Safety and Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty: A Pilot Study.
Tumscitz C, Campo G, Tebaldi M, Gallo F, Pirani L, Biscaglia S.
JACC Cardiovasc Interv. 2017 Jul 10;10(13):1375-1377. doi: 10.1016/j.jcin.2017.05.007. No abstract available.

Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, Tumscitz C, Moschovitis A, Windecker S, Valgimigli M.
Ann Intern Med. 2017 Jul 4;167(1):17-25. doi: 10.7326/M16-2389. Epub 2017 Jun 13.

Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis.
Pavasini R, Ruggerini S, Grapsa J, Biscaglia S, Tumscitz C, Serenelli M, Boriani G, Squeri A, Campo G.
Eur Heart J Cardiovasc Imaging. 2017 Jun 5. doi: 10.1093/ehjci/exz143. [

Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention.
Biscaglia S, Tebaldi M, Tumscitz C, Pavasini R, Marchesini J, Gallo F, Spitaleri G, Zaraket F, Serenelli M, Cimaglia P, Bugani G, Campo G.
Circ J. 2016 Dec 22;81(1):82-89. doi: 10.1253/circj.CJ-16-0785. Epub 2016 Nov 17.

Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter Italian Registry (the FREAK Study).
Tebaldi M, Biscaglia S, Fineschi M, Manari A, Menozzi M, Secco GG, Di Lorenzo E, D'Ascenzo F, Fabbian F, Tumscitz C, Ferrari R, Campo G.
Catheter Cardiovasc Interv. 2016 Oct;88(4):555-562. doi: 10.1002/ccd.26364. Epub 2015 Dec 31.

Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry
Simone Biscaglia, Gianluca Campo, Rita Pavasini, Matteo Tebaldi, Carlo Tumscitz & Roberto Ferrari-Platelets, 2016

Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multicenter Italian registry (the FREAK study)
M Tebaldi, S Biscaglia, M Fineschi... -
Catheterization and Cardiovascular Interventions 2015

Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE ...
S Biscaglia, G Campo, M Tebaldi, C Tumscitz
The international journal of Cardiology 2015 - Springer

Optical coherence tomography evaluation of overlapping everolimus-eluting biresorbable vascular scaffold implantation guided by enhanced stent visualization system.
Biscaglia S, Secco GG, Tumscitz C, Di Mario C, Campo G.
Int J Cardiol. 2014 Dec 28;182C:1-3. doi: 10.1016/j.ijcard.2014.12.103.

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalzone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators.
JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.

Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M.
J Am Coll Cardiol. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043. Epub 2013 Oct 23.
PMID: 24161321 [PubMed - indexed for MEDLINE]

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalzone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators.

Circulation. 2012 Apr 24;125(16):2015-26. doi: 10.1161/CIRCULATIONAHA.111.071589. Epub 2012 Mar 21.

Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry.

Valgimigli M, Saia F, Guastaroba P, Menozzi A, Magnavacchi P, Santarelli A, Passerini F, Sangiorgio P, Manari A, Tarantino F, Margheri M, Benassi A, Sangiorgi MG, Tondi S, Marzocchi A; REAL Registry Investigators.

JACC Cardiovasc Interv. 2012 Jan;5(1):23-35. doi: 10.1016/j.jcin.2011.08.018.

Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY).

Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, Zuffi A, Colombo F, Kubbajeh M, Cavazza C, Cangiano E, Tebaldi M, Minarelli M, Arcozzi C, Scalzone A, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R.

Am Heart J. 2010 Nov;160(5):804-11. doi: 10.1016/j.ahj.2010.07.034.

Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.

Valgimigli M, Campo G, de Cesare N, Vranckx P, Hamon M, Angiolillo DJ, Sabatè M, Ferrari F, Furgieri A, Tumscitz C, Repetto A, Colangelo S, Meliga E, Kubbajeh M, Parrinello G, Percoco G, Ferrari R. Cardiovasc Drugs Ther. 2008 Aug;22(4):313-20. doi: 10.1007/s10557-008-6121-z. Epub 2008 Jun 17.

Acute myocardial infarction caused by amphetamines: a case report and review of the literature.

Costa GM, Pizzi C, Bresciani B, Tumscitz C, Gentile M, Bugiardini R.

Ital Heart J. 2001 Jun;2(6):478-80. Review.